Evidence map›Paper›PMID 41223310›Full record

ArticleJMIR research protocols2026

Rapid Qualitative Approaches in Pandemic Research: Protocol for an Exploratory Qualitative Multimethod Study (VERDIQual) on Mpox in Italy, Nigeria, Thailand, and the United Kingdom.

Chinye Osa-Afiana, Marthe Le Prevost, Emily Jay Nicholls, Davide Bilardi, Thomas E Guadamuz, Esekwe E Soje-Amadosi, Grace I Adebisi, Chibueze Adirieje, Adeyosola A Adetunji, Karima Yusufu and 9 more

Abstract readMulticenter Study
In one paragraph

Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Chinye Osa-AfianaInternational Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.ORCID 0000-0001-9179-2100
Marthe Le PrevostMRC Clinical Trials Unit, University College London, London, United Kingdom.ORCID 0000-0001-5505-9809
Emily Jay NichollsInstitute for Global Health, University College London, London, United Kingdom.ORCID 0000-0003-2061-8361
Davide BilardiFondazione Penta, Padua, Italy.ORCID 0000-0002-8765-7384
Thomas E GuadamuzMahidol Center for Health, Behavior and Society, Faculty of Tropical Medicine, Mahidol University, Nakorn Pathom, Thailand.ORCID 0000-0001-6803-1127
Esekwe E Soje-AmadosiInternational Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.ORCID 0009-0007-3959-7747
Grace I AdebisiInternational Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.ORCID 0009-0009-3569-8270
Chibueze AdiriejeInternational Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.ORCID 0000-0001-5932-6687
Adeyosola A AdetunjiPediatric and Adolescent ART Unit, Department of Prevention, Care and Treatment, Institute of Human Virology Nigeria, Abuja, Nigeria.ORCID 0009-0001-0303-2687
Karima YusufuPediatric and Adolescent ART Unit, Department of Prevention, Care and Treatment, Institute of Human Virology Nigeria, Abuja, Nigeria.ORCID 0009-0005-3681-1643
T Charles WitzelInstitute for Global Health, University College London, London, United Kingdom.ORCID 0000-0003-4262-261X
Worawalan WaratworawanMahidol Center for Health, Behavior and Society, Faculty of Tropical Medicine, Mahidol University, Nakorn Pathom, Thailand.ORCID 0000-0001-8300-9892
Nattharat SamohMahidol Center for Health, Behavior and Society, Faculty of Tropical Medicine, Mahidol University, Nakorn Pathom, Thailand.ORCID 0000-0002-1000-6735
Tom MayNIHR Health Protection Research Unit in Evaluation and Behavioural Science, University of Bristol, Bristol, United Kingdom.ORCID 0000-0003-3077-523X
Sarah DenfordNIHR Health Protection Research Unit in Evaluation and Behavioural Science, University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-2123-1022
Willian GomesEuropean AIDS Treatment Group, Lisbon, Portugal.ORCID 0009-0004-4715-6376
Uzodinma AdiriejeAfrihealth Optonet Association, Abuja, Nigeria.ORCID 0000-0002-0275-3407
Shema Tariq *Institute for Global Health, University College London, London, United Kingdom.ORCID 0000-0001-9802-7727
Nadia Adjoa Sam-Agudu *International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.ORCID 0000-0001-5052-7730

Funding

Wellcome Trust 226345/Z/22/Z
6 · The paper itself

Abstract

backgroundRecent mpox outbreaks have underscored significant gaps in global preparedness for emerging and re-emerging infections. These outbreaks have disproportionately affected vulnerable and marginalized populations, exposing the weaknesses of health systems, particularly in resource-limited settings. The global spread of mpox beyond endemic African countries in 2022 and the emergence of a new Clade Ib in 2024 emphasize the pressing need for comprehensive and context-specific public health responses. We outline the protocol for an innovative multimethod qualitative study (VERDIQual [SARS-CoV-2 (and Mpox) Variants Evaluation in Pregnancy and Paediatrics Cohorts Qualitative Study]). This study is being conducted across 4 different countries and settings-Italy, Nigeria, Thailand, and the United Kingdom.

objectiveVERDIQual uses multiple qualitative methods to explore the lived experiences of different populations with mpox and frontline health care workers in endemic and nonendemic settings. With this approach, we aim to identify missed and new opportunities for effective public health messaging on prevention and treatment in this and future pandemics.

methodsVERDIQual's flexible, multimethod approach integrates content analysis of news and social media, focus group discussions, semistructured interviews, and participatory photography. We apply intersectionality theory to capture perspectives from a diverse range of participants, including gay, bisexual, and other men who have sex with men, pregnant women, adolescents with mpox, and frontline health care workers providing mpox services. Data will be collected and analyzed using the rapid assessment procedure approach, enabling real-time data synthesis to provide timely and contextually relevant insights. We use a standardized approach to data integration at the interpretation stage, summarizing findings in a multimethod integration matrix to visualize and synthesize data by objective, method, and site.

resultsData collection tools, including focus group discussions and semistructured interview topic guides, have been developed in collaboration with local community advisory boards. Data collection was completed by October 31, 2025, and analysis is ongoing. Teams across the 4 countries have identified media houses and social media platforms for inclusion in the news and social media analysis. Study results will be disseminated through peer-reviewed journals, scientific conferences, policy briefs, and stakeholder workshops and community events, with a focus on informing equitable and inclusive future public health responses to re-emerging infections.

conclusionsWe expect our principal findings to be applicable to a range of settings. Our use of intersectionality theory will also facilitate considerations for intersecting identities and characteristics in equity-centered pandemic responses. Ultimately, we expect VERDIQual to inform pandemic preparedness, inclusive of people with stigmatized and vulnerable characteristics or identities. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/77321.

Indexed as

COVID-19Mpox, MonkeypoxPandemicsSARS-CoV-2ChildFemaleFocus GroupsHumansItalyNigeriaPregnancyQualitative ResearchResearch DesignThailandUnited Kingdomglobal healthmonkeypoxmpoxpandemicsqualitative research

Identifiers

PMID41223310
PMCPMC12856405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.